Achtung-Girindus könnte ausbrechen !

Warum sollte Solvay aufstocken? Na, ganz einfach: Girindus besitzt viele Patente in einem GIGANTISCHEN Wachstumsmarkt:

The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. Factors driving market growth include growing R&D expenditure in pharmaceutical and biotech companies, emerging applications in molecular diagnostics and synthetic biology, and the evolving significance of RNA-interference oligos in therapeutics and diagnostics. However, regulatory barriers, especially for therapeutic oligos, and downward pricing pressure are the major factors restraining the growth of this market.

North America dominates the oligonucleotide synthesis market, with the U.S. accounting for the major market share. Asia-Pacific is poised to grow at the highest CAGR during the forecast period, owing to increasing R&D activities and funding, and the growing availability of synthesized oligos in this region. Many giant players are establishing their oligonucleotide manufacturing facilities in APAC to leverage market opportunity in the region. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotide manufacturing facility in Singapore to cater to research companies in APAC, thereby establishing its footprint in the APAC market. Such developments are further likely to spur growth in the APAC oligonucleotide synthesis market in the coming years.